Navigation Links
Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer
Date:5/5/2009

ravenous picoplatin include a Phase 3 trial in SCLC and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans and commercialization strategy, the timing and results of clinical trials and the potential safety and efficacy of the Company's products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market, the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
2. Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
3. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
4. Independent Study Corroborates Pranas Strategy to Treat Alzheimers Disease Patients.
5. Virginia Tech engineers investigate energy independent monitoring system for bridges
6. Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm
7. French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees)
8. Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
9. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
10. Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
11. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014) – The severe flooding that devastated a wide ... destructive if the bridges, roads and other infrastructure had ... from the University of Colorado Denver. , "People need ... Jimmy Kim, PhD, associate professor of structural engineering at ... and lead author the study. "There is an assumption ...
(Date:10/27/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) today ... the immunological response triggered by its novel proprietary ... of relapse in breast cancer patients. The AE37 ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... , October 27, 2014 Investor-Edge ... Inc. (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... As the Office of Naval Research (ONR) increases its ... number of hurdles need to be overcome including autonomy ... an Aug. 18 conference on unmanned systems. "We ... for the Navy and Marine Corps," said Dr. Larry ...
... developed new nano-structured glass, turning it into new type ... and will significantly reduce the cost of medical imaging. ... converter created by femtosecond laser nanostructuring of glass published ... by Professor Peter Kazansky at the University,s Optoelectronics Research ...
... Aug. 18, 2011 CBI is pleased to announce ... and Post-Approval Studies Congress, being held September 20-22, 2011 ... an impressive speaker lineup from Celgene, Covidien, FDA, Forest, ... more. Attendees have the opportunity to ...
Cached Biology Technology:Office of Naval Research taking on challenges of unmanned underwater vehicles 2New nanostructured glass for imaging and recording 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:10/28/2014)... tragic realities of cancer is that the drugs ... their effectiveness varies unpredictably from patient to patient. ... change this reality by rapidly assessing how effective ... cancer before chemotherapy begins. , A team of ... Professor Melissa Skala has developed the technique, which ...
(Date:10/28/2014)... Researchers from the National University of Singapore (NUS) have ... - breeding and laying direct developing eggs in live ... the white spotted bush frog ( Raorchestes chalazodes ... of two species known to adopt this novel reproductive ... of London,s Biological Journal of the Linnean Society ...
(Date:10/27/2014)... University researchers have delivered a scientific one-two punch with ... fibers self-assemble via their sticky ends. , Collagen is ... of bone and the fibrous tissues that support cells ... to better synthetic collagen for tissue engineering and cosmetic ... Hartgerink has been studying synthetic collagen for a decade, ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... team of French and German researchers report in the ... http://www.fasebj.org ) that people with limb-girdle muscular dystrophy are ... to prevent the loss of muscle tissue. By targeting ... protein, scientists could develop new drugs to stop muscle ...
... thing could be harmful to the environment. For years, ... bacteria and, recently, have used this knowledge to create ... Missouri researcher has found that silver nanoparticles also may ... from wastewater treatment systems. The study was funded by ...
... and Canadian scientists expect to begin trials next month (May) ... of energy trapped in the world,s unrecoverable heavy oil deposits. ... because the oil has become either solid or too thick ... conventional means. , However, scientists at Newcastle University, England, and ...
Cached Biology News:Researchers discover molecular basis of a form of muscular dystrophy 2Too much technology may be killing beneficial bacteria 2Scientists aim to boost world energy supplies -- with microbes! 2Scientists aim to boost world energy supplies -- with microbes! 3Scientists aim to boost world energy supplies -- with microbes! 4